Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Kanako Yajima"'
Autor:
Kanako YAJIMA, Yuuta TERASAKA, Tomohiro NAKASHIMA, Yuki HATTORI, Noriaki KATAOKA, Ryuta YAMADA, Shougo MORITA, Takahiro NAKAYAMA, Tsugufumi MATSUYAMA, Yuuki WATANABE, Mitsuaki OKA, Junichi TAIRA, Takahiro WATANABE
Publikováno v:
Japanese Journal of Health Physics. 50:111-116
Autor:
Kanako Yajima, Mikiko Hikawa, Masaki Takada, Norie Murayama, Yasuhiro Uno, Yu Ishii, Kanami Shimura, Hiroshi Yamazaki, Masahiro Utoh, Kazuhide Iwasaki
Publikováno v:
Biopharmaceuticsdrug disposition. 39(2)
The fraction of substrate metabolized (fm ) can be used to estimate drug interactions and can be determined by comparison of the intrinsic clearances (CLint ) of victim drugs obtained from inhibited and uninhibited hepatic enzymes. Commercially avail
Autor:
Makiko Shimizu, Christiane Guillouzo, F. Peter Guengerich, Norio Shibata, Rinie van Beuningen, Kanako Yajima, Christophe Chesne, Hiroshi Yamazaki, Masahiro Utoh, Hiroshi Suemizu, Norie Murayama, René Houtman, Masato Nakamura
Publikováno v:
Chemical Research in Toxicology. 27:304-308
Heterotropic cooperativity of human cytochrome P450 (P450) 3A4/3A5 by the teratogen thalidomide was recently demonstrated by H. Yamazaki et al. ( ( 2013 ) Chem. Res. Toxicol. 26 , 486 - 489 ) using the model substrate midazolam in various in vitro an
Autor:
Tomohiro NAKASHIMA, Ryuta YAMADA, Kanako YAJIMA, Jun HIROUCHI, Noriaki KATAOKA, Yoshitaka SHIROMA, Takahiro WATANABE, Naoyuki KANDA, Yuta TERASAKA, Junichi TAIRA, Mitsuaki OKA, Shingo OZAWA
Publikováno v:
Japanese Journal of Health Physics. 49:123-127
Autor:
Mitsuya Shiraishi, Kanako Yajima, Noriaki Miyoshi, Hiroaki Kawaguchi, Atsushi Miyamoto, Hidetomi Kadokura, Rie Yamashita, Tsuyoshi Yoshikawa, Hideyuki Yamatoya
Publikováno v:
Experimental Animals. 61:467-476
The aim of this study was to collect data on chronological changes in clinical laboratory tests, pathological examinations, and hepatic drug-metabolizing enzymes from Wistar Hannover rats at 8, 10, 19, and 32 weeks of age. The serum triglyceride conc
Autor:
Takashi Matsuyama, Mutsuko Hirata-Koizumi, Akihiko Hirose, Mitsuhiko Kawabata, Kiyomi Matsuno, Eiichi Kamata, Kanako Yajima, Makoto Ema
Publikováno v:
Drug and Chemical Toxicology. 32:204-214
Previously, we showed that the toxic susceptibility of male rats to an ultraviolet absorber, 2-(2'-hydroxy- 3',5'-di-tert-butylphenyl)benzotriazole (HDBB), was nearly 25 times higher than that of females. The present study aimed to clarify the mechan
Publikováno v:
YAKUGAKU ZASSHI. 128:1459-1465
Beraprost sodium (BPS), a chemically stable and orally active prostacyclin analogue used for the treatment of chronic occlusive disease and primary pulmonary hypertension, was investigated in terms of its drug-drug interaction mediated by cytochrome
Autor:
Kanako Yajima, Norie Murayama, Shotaro Uehara, Chika Nakamura, Yasuhiro Uno, Makiko Shimizu, Kazuhide Iwasaki, Hiroshi Yamazaki, Masahiro Utoh
Publikováno v:
Drug metabolism and disposition: the biological fate of chemicals. 42(5)
Due to the importance of in vitro cytochrome P450 (P450) induction assay to assess the possible drug-drug interaction events, the recent US Food and Drug Administration draft guidance and European Medicines Agency guideline recommend to assess P450 i
Autor:
Takafumi Iwatsubo, Shotaro Uehara, Aiji Miyashita, Kanako Yajima, Shin Takusagawa, Takashi Usui
Publikováno v:
Xenobiotica; the fate of foreign compounds in biological systems. 42(10)
1. Human cytochrome P450 (CYP) enzymes and esterases involved in the metabolism of mirabegron, a potent and selective human β(3)-adrenoceptor agonist intended for the treatment of overactive bladder, were identified in in vitro studies. 2. Incubatio
Autor:
Katsuhiro Suzuki, Tadashi Hashimoto, Aiji Miyashita, Takafumi Iwatsubo, Takashi Usui, Kanako Yajima, Takuya Teragaki, Toshifumi Shiraga
Publikováno v:
Biologicalpharmaceutical bulletin. 35(3)
Darexaban maleate is a novel oral direct factor Xa inhibitor. Darexaban glucuronide (YM-222714) was the major component in plasma after oral administration of darexaban to humans and is the pharmacologically active metabolite. Additionally, YM-222714